CD103+ DCs, a subtype with high capacity for antigen cross‐presentation to T cells,41 were also quantified in the tumor with flow cytometry to inform on the antigen presentation stage of the cancer‐immunity cycle. This evidence concerns the gene ITGAE and neoplasm.